According to a report by the media outlet Ismorbo on January 22, the U.S. Food and Drug Administration (FDA) recently revealed that cannabis is considered to have legitimate medical uses and has proposed reclassifying it from a Schedule I substance to a Schedule III substance. This decision has sparked widespread attention and discussion.
The FDA has stated that compared to other substances classified as Schedule I or II drugs, marijuana poses a lower threat to public health. While some individuals may face risks due to excessive use of marijuana, the majority of marijuana users do not pose significant risks to themselves or others.
When assessing the risks and benefits of marijuana, the FDA has chosen to use alcohol as a reference standard, despite alcohol not being classified as a controlled substance. The agency acknowledges that there is scientific evidence supporting the use of medical marijuana in treating various symptoms, including but not limited to appetite loss, anxiety disorders, epilepsy, inflammatory bowel diseases, nausea and vomiting, pain, and post-traumatic stress disorder. However, the FDA emphasizes that this does not mean that the safety and effectiveness of marijuana have been fully established.
This proposal could provide more operational freedom for cannabis companies and alleviate tax restrictions dating back 40 years. However, the decision does not explicitly endorse the use of marijuana for treating specific health conditions. This reclassification could also stimulate further research on cannabis, opening up new possibilities for the future development of this field. The long-term impact of this decision on the cannabis industry and related sectors is being closely watched.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
